CaMKK2 as a target for cancer immunotherapy
Tumor cells have the remarkable ability to block the immune system, and in such a way escape the immune response. This is a major problem that causes cancer development and metastasis. The ability of tumor cells to blunt the immune response is also a major limitation for the recent immune-therapeutic approaches, including anti-cancer vaccines and immune-check point inhibitors. This invention is aimed at preventing the detrimental effects of tumor on immune cells, and in such a way at activating the anti-tumor immune response. The invention can be used as mono-therapy to promote the anti-cancer immune response, or in association with other anti-cancer therapies, including radio- chemo- and immune-therapies.